| (1) |
Singer PA, Cooper DS, Daniels GH, ct al. Treatment guidelines for patients
with thyroid nodules and well-differentiated thyroid cancer. Arch Intern
Med 1996; 156: 2165-72. |
| (2) |
AACE clinical practice guidelines for the management of thyroid carcinoma.
Endocr Pract 1997; 3: 60-71. |
| (3) |
Solomon BL, Wartofsky L, Burman KD. Current trends in the management ofwell
differentiated papillary thyroid carcinoma. J Clin Endocrinol Metab 1996;
81: 333-9. |
| (4) |
Parkin DM, Muir CS, Whelan SL, Gao YT, Ferkry J, Powell J. Cancer incidence in five continents. Vol. 6. Lyon, France: International Agency for Research on Cancer, 1992. (IARC scientific publications no. 120.) |
| (5) |
Fagin JA. Molecular pathogcnesis. In: Braverman LE, Utiger RD, cds. Werner
and Ingbar's the thyroid: a fundamental and clinical text. 7th ed. Philadelphia:
Lippincott-Raven, 1996: 909-16. |
| (6) |
Fusco A, Grieco M, Santoro M, et al. A new oncogene in human thyroid papiliary
carcinomas and their lymph-nodal metastases. Nature 1987; 328: 170-2. |
| (7) |
Santoro :M, Carlomagno F, Hay ID. et al. Ret oncogene activation in human
thyroid neoplasms is restricted to the papillary cancer subtype. J Clin
Invest 1992; 89: 1517-22. |
| (8) |
Bongdrzone I, Fugazzola L, Vigneri P, et al. Age-relatcd activation of
the tyrosine kinase receptor protooncogcnes RET and NTRKI in papillary thyroid
carcinoma. J Clin Endocrinol Mctab 1996; 81: 2006-9. |
| (9) |
Zou M, Shi Y, Farid NR. Low rate of ret proto-oncogcne activation (PTC/RETtpc) in papillary thyroid carcinomas from Saudi Arabia. Cancer l994;73 :176-80. |
| (10) |
Fugazzola L, Pilotti S, Pinchera A, et al. Oncogenic rearrangements of
the RET proto-oncogene in papillary thyroid carcinomas from children exposed
to the Chernobyl nuclear accidcnt. Cancer Res 1995; 55: 5617-20. |
| (11) |
Klugbauer S, Lengfelder E, Demidehik EP-, Rabes HM. Higb prevalenceof
RET rearrangement in thyroid tumors of children from Belarus after the Chernobyl
rcactor accident. Oncogene 1995; 11: 2459-67. |
| (12) |
Nikiforov YE, Rowland JM, Bove KE, Monforte-Munoz H, Fagin JA. Distinct
pattern of ret oncogene rearrangements in morphoiogical variants of radiation-induced
and sporadic thyroid papillary carcinomas in children. Cancer Res 1997;
57: 1690-4. |
| (13) |
Bounacer A, Wicker R, Caillou B, et al. High prevalence of activating
RET proto-oncogene rearrangements in thyroid tumors from patients who had
received external radiation. Oncogene 1997; 15: 1263-73. |
| (14) |
Challeton C, Bounacer A, Du Villard JA, et al. Pattern of ras and gsp
oncogene mutations in radiation-associated human thyroid tumors, Oncogene
1995; 11: 601-3. |
| (12) |
Russo D, Arturi F, Schlumberger M, et al. Activating mutations of the
TSH receptor in differentiated thyroid carcinomas. Oncogene 1995; 11: 1907-11. |
| (16) |
Fagin JA, Matsuo K, Karmakar A: Chen DL, Tang SH, Koeffler HP. High prevalenec
of mutations of the p53 gene in poorly differentiated human thyroid carcinomas.
J C]in Invest 1993; 91: 179-84. |
| (17) |
Ito T, Seyama T, Mizuno T, et al. Unique association of p53 mutations
with undifferentiated but not with differentiated carcinomas of the thyroid
gland. Cancer Res 1992; 52: 1369-71. |
| (18) |
Shore KE. lssues and cpidemiological evidencne regarding radiationinduced thyroid cancer. Radiat Res 1992;131:98-111. |
| (19) |
Ron E, Lubin JH, Shore RE, et al. Thyroid cancer after exposure to external
radiation: a pooled analysis of seven studies. Radiat Res 1995; 141: 259-77. |
| (20) |
Schneider AB, Ron E. Pathogenesis. In: Braverman LE; Utiger RD, eds. Werner
and Ingbar's the thyroid: a fundamental and clinical text. 7th ed. Philadelphia:
Lippincott-Raven, 1996: 902-9. |
| (21) |
Dobyns BM, Hyrmer BA. The surgical managcment of benign and malignant
thyroid neoplasms in Marshall Islanders cxposed to hydrogen bomb fallout.
World J Surg 1992; 16: 126-40. |
| (22) |
Kazakov VS, Demidchik F.P, Astakhova LN. Thyroid cancer after Chernobyl.
Nature 1992; 359: 21. |
| (23) |
Franceschi S, Boyle P, Maisonneuve P, et al. The epidemiology ofthyroid
carcinoma. Crit Rev Oncog 1993; 4: 25-52. |
| (24) |
Goldgar DF.,Easton DF, Cannon-Albright LA, Skolnick MH. Systematic population-based
assessment of cancer risk in first-degree relatives of cancer probands.
J Natl Cancer Inst 1994; 86: 1600-8. |
| (25) |
Hedinger C, Williams ED, Sobin LH. Histological typing of thyroid tumours.
2nd ed. No. 11 of International histological classification of tumours.
Berlin, Germany: Springer-Verlag. 1988. |
| (26) |
Rosai I, Carcangiu ML, Deleilis RA. Tumors ofthe thyroid gland. In: Atlas
of tumor pathology. 3rd series. Fascicle 5. Washingron, D.C. : Armed Forces
Institute of Pathology, 1992. |
| (27) |
Mazzaferri EL. Managcment of a solitary thyroid nodule. N Engl J Med 1993;
328: 553-9. |
| (28) |
Byar DP, Green SB. Dor P, et al. A prognostic index for thyroid carcinoma:
a study of the EORTC Thyroid Cancer Cooperative Group. Eur J Cancer 1979;
15: 1033-41. |
| (29) |
Cady B, Rossi R. An expanded view ofrisk-group dcfinition in differentiated
thyroid carcinoma. Surgery 1988; l04: 947-53. |
| (30) |
DeGroot LJ, Kaplan F.L, McConnick M, Straus FH. Natural history, treatment,
and course ofpapillary thyroid carcinoma. J Clin Endocrinol Metab 1990;
71: 414-24. |
| (31) |
Hay ID, Bergstralh EJ, Goellner JR, Ebersold JR, Grant CS. Predicting
outcome in papillary thyroid carcinoma: development of a reliable prognostic
scoring system in a cohort of 1779 patients surgically treated at one institution
during 1940 through 1989. Surgery 1993; 114: 1050-8. |
| (32) |
Hay ID, Grant CS, Taylorwr, McConahey WM. Ipsilateral lobectomy versus
bilateral lobar resection in papillary thyroid carcinoma: a retrospective
analysis ofsurgical outcome using a novel prognostic scoring system. Surgery
1987; 102: 1088-95. |
| (33) |
Thyroid g]and. In: Hermanck P, Sobin LH, eds. TNM classification of malignant
tumors. 4th ed. 2nd rev. Berlin, Germany: Springer-Verlag, 1992: 35-7. |
| (34) |
Brierley JD, Panzarella T, Tsang RW, Gospodarowicz MK, O'Sullivan B. A
comparison of different staging systems predictability of patient outcome:
thyroid carcinoma as an example. Cancer 1997; 79: 2414-23. |
| (35) |
Mazzaferri EL, Jhiang SM. Long-term impact of initial surgical and medical
therapy on papillary and follicular thyroid cancer. Am J Med 1994; 97:418-28.
[Erratum, Am J Med 1995; 98: 215.] |
| (36) |
Samaan NA, Schultz PN. Hickcy RC; et al. The results ofvarious modalities
of treatment of well diftbrentiated thyroid carcinoma: a retrospective review
of 1599 patients. J Clin Endocrinol Metab 1992; 75: 714-20. |
| (37) |
Simpson WJ, Panzarella T, Carruthers JS, Gospodarowicz MK, Sutcliffe SB.
Papillary and foilicular thyroid cancer: impact of treatment in 1578 patients.
Int J Radiat Oncol Biol Phys 1988; 14: 1063-75. |
| (38) |
Tubiana M, Schlumberger M, Rougier P, ct al. Long-term results and prognostic
factors in patients with differentiated thyroid carcinoma. Cancer 1985;
55: 794-804. |
| (39) |
Schiumbcrger M, De Vathaire F, Travagli JP, et al. Differentiated thyroid
carcinoma in childhood: Iong term fbllow-up of 72 patients. J Clin Endocrinol
Mctab 1987; 65: 1088-94. |
| (40) |
Vassilopoulou-Sellin R, Kicin MJ, Smith TH, et al. Pulmonary metastases
in children and young adults with differentiated thyroid cancer. Cancer
1993; 71: 1348-52. |
| (41) |
Sakamoto A, Kasai N, Sugano H. Poorly differentiated carcinoma of the
thyroid: a clinicopathologic entity for a high-risk group of papillary and
follicular carcinomas. Cancer 1983; 52: 1849-55. |
| (42) |
Hay ID, Grant CS, Van Heerden ;A, Goellner JR, Ebersold JR, Bergstralh
EJ. Papillary thyroid microcarcinoma: a study of 535 cascs observed in a
50-year period. Surgery 1992; 112: 1139-46. |
| (43) |
Demeure MJ, Clark OH. Surgery in the treatment of thyroid cancer. Endocrinol
Metab Clin North Am 1990; 19: 663-83. |
| (44) |
Katoh R, Sasaki J, Kurihara H, Suzuki K, Iida Y, Kawaoi A. Multiple thyroid,
involvement (intraglanduiar metastasis) in papillary thyroid carcinoma:
a clinicopathologic study of 105 consecutive patients, Canccr 1992; 70:
1585-90. |
| (45) |
Russell WO, Ibanez ML, Clark RL. White EC. Thyroid carcinoma: Classification,
intraglandular dissemination, and clinicopathological study based upon whole
organ sections of 80 glands. Cancer 1963; 16: 1425-60. |
| (46) |
Grebe SKG, Hay ID. Thyroid cancer nodal mctastases: biologic significance.
and therapeutic considerations. Surg Oncol Clin North Am 1996; 5: 43-63. |
| (47) |
Sherman SI, Tielens ET, Sostre S, Wharam MD Jr, Ladenson PW. Clinical
utility of posttreatment radioiodine scans in the management of patients
with thyroid carcinoma. J Clin Endocrinol Mctab 1994; 78: 629-34. |
| (48) |
Tenenbaum F, Corone C, Schlumberger M, Parmentier C. Thyroglobulin measurement
and postablative iodine-131 total body scan after total thyroidectomy for
differentiated thyroid carcinoma in patients with no evidence of disease.
Eur J Cancer 1996; 32A: 1262. |
| (49) |
Maxon HR III, Smith HS. Radioiodine-131 in the diagnosis and treatment
of metastatic well differentiated thyroid cancer. Endocrinol Metab Glin
North Am 1990; 19: 685-718. |
| (50) |
Maxon HR III, Englaro EE, Thomas SR. et al. Radioiodine-131 therapy for
well-differentiated thyroid cancer quantitative radiation dosimetric approach:
outcome and validation in 85 patients. J Nucl Med 1992; 33: 1132-6. |
| (51) |
Tubiana M, Haddad E, Schlumberger M, Hill C, Rougier P, Sarrazin D. Extemal radiotherapy in thyroid cancers. Cancer 1985;55:Suppl:2062-71. |
| (52) |
Bartalcna L, Martino E, Pacchiarotti A, et al. Factors affecting suppression
of endogenous thyrotropin secretion by thyroxine treatment: retrospective
analysis in athyreotic and goitrous patients. J Clin Endocrinol Metab 1987;
64: 849-55. |
| (53) |
Marcocci C, Golia F, Bruno-Bossio G, Vignali E, Pinchcra A. Carefully
monitored levothyroxine suppressive therapy is not associated with bone
loss in premenopausal women. J Clin Endocrinol Metab 1994; 78: 818-23. |
| (54) |
Pacini. F, Fugazzola L, Lippi F, et al. Detection of thyroglobulin in
fine needle aspirates of nonthyroidal neck masses: a clue to the diagnosis
of metastatic differentiated thyroid cancer. J Clin Endocrinol Metab 1992;
74: 1401-4. |
| (55) |
Schlumberger M, Challeton C, Dc Vathaire F, ct al. Radioactive iodine
treatment and external radiotherapy for lung and bone metastases from thyroid
carcinoma.J Nucl Med 1996; 37: 598-605. |
| (56) |
Van Herle AJ, Uller RP, Matthews NI, Brown J. Radioimmunoassay for measurement
of thyroglobulin in human serum. J Clin Invest 1973; 52: 1320-7. |
| (57) |
Schlumberger M. Follow-up of paticnts with differentiated thyroid carcinoma.
In: Johnson JT, Didolkar MS, eds. Head and neck cancer. Vol. 3. Amsterdam:
Elsevier Science, 1993: 903-10. |
| (58) |
Mariotti S, Barbesino G, Caturegli P, et al. Assay of thyroglobulin in
serum with thyroglobulin autoantibodies: an unobtainable goal? J Clin Endocrinol
Metab 1995; 80: 468-72. |
| (59) |
Schlumberger M, Charbord P, Fragu P, Lumbroso J, Parmentier C, Tubiaha
M. Circulating thyroglobulin and thyroid hormones in patients with metastases
of differentiated thyroid carcinoma: relationship to serum thyrotropin levels.
J Clin Endocrinol Metab 1980; 51: 513-9. |
| (60) |
Schneider AB, Line BR. Goldman IM, Robbins J. Sequential serum thyroglobulin
determinations, 131-I scans, and 131-I uptakes after triiodothyronine withdrawal
in patients with thyroid cancer. J Clin Endocrinol Metab 1981; 53: 1199-206. |
| (61) |
Schlumberger M, Fragu P, Parmentier C, Tubiana M. Thyroglobulin assay
in the follow-up of patients with differentiated thyroid carcinomas: comparison
of its value in patients with or without normal residual tissue. Acta Endocrinol
(Copenh) 1981; 98: 215-21. |
| (62) |
Ozata M, Suzuki S, Miyamoto T, Liu RT, Ficrro-Renoy F, DeGroot LJ. Serum
thyroglobulin in the follow-up of patients with treated difrerentiated thyroid
cancer. J Clin Endocrinol Mctab 1994; 79: 98-105. |
| (63) |
Ashcraft M. W, Van Herle AJ, The comparative value of serum thyrogiobulin
measurements and iodine 131 total body scans in the follow-up study of patients
with treated differentiated thyroid cancer. Am J Med 1981; 71: 806-14. |
| (64) |
Pacini F, Lari R, Mazzeo S, Grasso L, Taddei D, Pinchera A. Diagnostic
value of a single serum thyroglobulin determination on and off thyroid suppressive,
therapy in the follow-up of patients with differentiated thyroid cancer.
Clin Endocrinol (Oxf)1985; 23: 405-11. |
| (65) |
Paccini F, Lippi F, Formica N, ct al. Therapeutic doses of iodine-131
reveal undiagnosed metastases in thyroid cancer patients with detectable
serum, thyrogiobulin levels. J Nucl Med 1987; 28: 1888-91. |
| (66) |
Schlumberger M, Arcangioli O, Piekarski ID, Tubiana M, Parmentier C. Detection
and treatment of lung metastases of differentiated thyroid carcinoma in
patients with normal chest X-rays. J Nucl Med 1988; 29: 1790-4. |
| (67) |
Pineda JD, Lee T, Ain K, Reynolds JC, Robbins J. Iodine-131 therapy for
thyroid cancer patients with clevated thyroglobulin and negative diagnostic
scan. J Clin Endocrinol Metab 1995; 80: 1488-92. |
| (68) |
Mazzaferri EL. Treating high thyroglobulin with radioiodine: a magic bullet
or a shot in thc dark? J Clin Endocrinol Metab 1995; 80: 1485-7. |
| (69) |
Goldman JM, Line BR, Aamodt RL, Robbins J. Influence of triiodothyronine
withdrawal time on 131-I uptake postthyroidectomy for thyroid cancer. J
Clin Endocrinol Metab 1980; 50: 734-9. |
| (70) |
Guimaraes V, DeGroot LJ. Moderate hypothyroidism in preparation for whole
body 131-I scintiscans and thyroglobulin testing. Thyroid 1996; 6: 69-73. |
| (71) |
Ladenson PW, Braverman LE, Mazzaferri EL, et al. Comparison of administration
of recombinant human thyrotropin with wirhdrawal of thyroid hormone for
radioactive iodine scanning in patients with thyroid carcinoma. N Engl J
Med 1997; 337: 888-96. |
| (72) |
Regalbuto C, Gullo D, Vigneri R. Pezzino V. Measuremcnt of iodine before
131-I in thyroid cancer. Lancet 1994; 344: 1501-2. |
| (73) |
Park HM, Perkins OW, Edmondson JW, Schnute RB, Manatunga A. Influence of diagnostic radioiodines on thc uptake of ablative dose of iodine-131. Thyroid 1994;4:49-54. |
| (74) |
Tenenbaum F, Schlumbcrger M, Bonnin F, ct al. Usefulness of technetium-99m
hydroxymethylene diphosphonate scans in localizing bone metastases of differentiated
thyroid carcinoma. Eur I Nucl Med 1993; 20: 1168-74. . |
| (75) |
Hoefnagel C.A, Delprat CC, Marcuse HR, de Vijlder JJM. Role of thallium-201
total-body scintigraphy in follow-up of thyroid carcinoma. J Nucl Med 1986;
27: 1854-7. |
| (76) |
Lind P, Gallowitsch HJ, Langsteger W, Kresnik E, Mikosch P, Gomez I. Technetium-99m-tetrofosmin
whole-body scintigraphy in the follow-up of differentiated thyroid carcinoma.
J Nutl Med 1997; 38: 348-52. |
| (77) |
Feine U, Lietzenmayer R, Hanke JP, Held J, Wohrle H, Muller-Schauenburg
W. Fluorine-18-FDG and iodine-131-iodide uptake in thyroid cancer. J Nucl
Med 1996; 37: 1468-72. |
| (78) |
Ricard M, Tenenbaum F, Schlumberger M, ct al. Intraoperative detection
of pheochromocytoma with iodine-125 Iabelled meta-iodobenzylguanidine: a
feasibility study. Eur J Nucl Med 1993; 20: 426-30. |
| (79) |
Hoie I, Stenwig AE, Kullmann G, Lindegaard M. Distant metastases in papillary
thyroid cancer: a review of 91 patients. Cancer 1988; 61: 1-6. |
| (80) |
Marcocci C, Pacini F, Elisci R, et al. Clinical and biologic behavior
of bone metastases from differentiated thyroid carcinoma. Surgery 1989;
106: 960-6. |
| (81) |
Niederle B, Roka R, Schemper M, Fritsch A, Weissel M, Ramach W. Surgical
treatment of distant metastases in differentiated thyroid cancer: indication
and results. Surgery 1986; 100: 1088-97. |
| (82) |
Maxon HR, Thomas SR, Hertzberg VS, et al. Relation between effective radiation
dose and outcome of radioiodine therapy for thyroid cancer. N Engl J Med
1983; 309: 937-41. |
| (83) |
Shimaoka K, Schoenfeid DA, DeWys WD, Creech RH, DeConti R. A randomized
triai of doxorubicin versus doxorubicin plus cisplatin in patients with
advanced thyroid carcinoma. Cancer 1985; 56: 21 55-60. |
| (84) |
Williams SD, Birch R, Einhorn LH. Phase II evaluation of doxorubicin plus
cisplatin in advanced thyroid cancer: a Southeastem Cancer Study Group Trial.
Cancer Treat Rep 1986; 70: 405-7. |
| (85) |
Casara D, Rubelio D, Saladini G, et al. Different features of pulmonary
metastases in differentiated thyroid cancer: natural history and multivariate
statistical analysis of prognostic variables. J Nucl Med 1993; 34: 1626-31. |
| (86) |
Dinneen SF, Vaiimaki MI, Bergstralh EJ, Goellner JR, Gorman CA, Hay ID.
Distant metastases in papillary thyroid carcinoma: 100 cases observed at
one institution during 5 decades. J Clin Endocrinol Metab 1995; 80: 2041-5. |
| (87) |
Rall JE, Alpers JB, Lewallen CG, Sonenberg M, Berman M, Rawson RW. Radiation
pneumonitis and fibrosis: a complication of radioiodine treatment of pulmonary
metastases from cancer of the thyroid. J Clin Endocrinol Metab 1957; 17:
1263-76. |
| (88) |
Pacini F, Gasperi M, Fugazzola L, et al. Testicular function in patients
with differentiated thyroid carcinoma treated with radioiodine. J Nucl Mcd
1994; 35: 1418-22. |
| (89) |
kaymond JP, Izembart M, Marliac V, et al. Temporary ovarian failure in
thyroid cancer patients after thyroid remnant ablation with radioactive
iodine. J Clin Endocrinol Metab 1989; 69: 186-90. |
| (90) |
Dottorini ME, Lomuscio G, Mazzucchclli L, Vignati A, Colombo L. Assessment
of female fertility and carcinogcnesis after iodine-131 therapy for differentiated
thyroid carcinoma. J Nucl Med 1995; 36: 21-7. |
| (91) |
Schlumberger M, Dc Vathaire F, Ccccarclli C, et al. Exposure to radioactive
iodine-131 for scintigraphy or therapy does not preclude preg-nancy in thyroid
cancer patients. J Nucl Med 1996; 37: 606-12. |
| (92) |
de Vathaire F, Schlumberger M, Delisle MJ, ct al. Leukacmias and cancers
following iodine-131 administration for thyroid cancer. Br J Cancer 1997;
75: 734-9. |
| (93) |
Hall P, Holm LE, Lundell G, et al. Cancer risks in thyroid cancer patients.
Br J Cancer 1991; 64: 159-63. |